Eris Lifesciences enters into insulin segment

Eris has formed a JV with MJ Biopharm for this purpose.

Key points to note –

  • Eris will hold 70% of the JV and MJ 30%.
  • MJ is also getting Rs 15 crore as one time lump sum licence fee.
  • MJ will be responsible for development of products and Eris marketing of those.

JV seems to be a step in the right direction.

Companies -
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x